Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
61-80 of 998 trials

Acute Ischemic Stroke: Redasemtide Study

We are investigating whether redasemtide can improve recovery in adults who have had an acute ischemic stroke. Participants will receive either the medication or a placebo to compare effects.

Ischaemic Stroke>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Rituximab for Heart Attack Recovery

We are studying whether a single injection of rituximab can improve heart function in patients who have had a heart attack. This trial compares its effects to a placebo to see if it helps reduce heart damage.

ST Segment Elevation Myocardial InfarctionAcute Myocardial Infarction>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Inclusion Body Myositis: ABC008 Treatment Study

We are studying the safety and effectiveness of a new treatment called ABC008 for people with Inclusion Body Myositis. The goal is to see if it improves muscle function and strength compared to a placebo.

Inclusion Body Myositis1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyRheumatology

Isolated MMA: Long-Term Study of mRNA-3705

We are evaluating the long-term safety and effects of mRNA-3705 in individuals with Isolated MMA who have participated in earlier studies. This research aims to understand how the treatment impacts health and daily activities over time.

Methylmalonic AciduriaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal Medicine

Crohn's Disease: Risankizumab for Children

We are studying the safety and effectiveness of risankizumab in children aged 2 to under 18 with moderately to severely active Crohn's disease. This trial aims to help those who haven't responded to other treatments.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

H3 K27M-Mutant Diffuse Glioma: ONC201 Treatment Study

We are studying the effects of ONC201 in patients with H3 K27M-mutant diffuse glioma after radiotherapy. The goal is to see if it improves outcomes compared to a placebo.

H3 K27M-Mutant Diffuse GliomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Zilucoplan for Children with Generalized Myasthenia Gravis

We are studying the long-term safety of zilucoplan in children with generalized myasthenia gravis who participated in an earlier trial. This research aims to understand how well the treatment works and its effects over time.

Myasthenia GravisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Semaglutide for Glucose Intolerance in Women with Prior Gestational Diabetes

We are studying whether semaglutide can help women with a history of gestational diabetes manage glucose intolerance and reduce the risk of developing type 2 diabetes.

Prediabetes>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGynecology and Obstetrics

Small Cell Lung Cancer: Niraparib with Immunotherapy

We are studying the effects of adding niraparib to immunotherapy for patients with SLFN11-positive small cell lung cancer. This research aims to see if it improves treatment after initial therapy.

Extensive Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Primary IgA Nephropathy: RO7434656 Treatment Study

We are testing a new medication to see if it helps reduce protein in urine and improves kidney function in patients with Primary IgA Nephropathy at high risk of progression. The study will also evaluate safety and fatigue levels.

IgA Nephropathy>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Kidney Disease: Iptacopan (LNP023) Study

We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.

Idiopathic Immune Complex Mediated Membranoproliferative GlomerulonephritisConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Focal-Onset Seizures: Study of XEN1101

We are testing a new medication, XEN1101, to see if it can help reduce the frequency of focal-onset seizures. This study compares its effects to a placebo in participants with this condition.

Focal Epilepsy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology